Experienced in Hepatic Hemangioma

Dr. Brian D. Weiss

General Surgery | Emergency Medicine
Jefferson University Physicians
111 S 11th St, 
Philadelphia, PA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Experienced in Hepatic Hemangioma
Jefferson University Physicians
111 S 11th St, 
Philadelphia, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Brian Weiss is a General Surgeon and an Emergency Medicine provider in Philadelphia, Pennsylvania. Dr. Weiss is rated as an Experienced provider by MediFind in the treatment of Hepatic Hemangioma. His top areas of expertise are Neurofibromatosis, Ganglioneuroblastoma, Aplasia Cutis Congenita, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Weiss is currently accepting new patients.

His clinical research consists of co-authoring 58 peer reviewed articles and participating in 20 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Hepatic Hemangioma.

Specialties
General Surgery
Emergency Medicine
Licenses
Emergency Medicine in OH
Hospital Affiliations
Thomas Jefferson University Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

CareSource
  • HMO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID

Locations

JEFFERSON UNIVERSITY PHYSICIANS
111 S 11th St, Philadelphia, PA 19107

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

20 Clinical Trials

A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
Enrollment Status: Recruiting
Publish Date: October 10, 2025
Intervention Type: Drug, Procedure, Biological, Radiation
Study Drugs: Busulfan, Carboplatin, Cisplatin, Crizotinib, Cyclophosphamide, Dexrazoxane Hydrochloride, Dinutuximab, Doxorubicin Hydrochloride, Etoposide Phosphate, Isotretinoin, Melphalan Hydrochloride, Sargramostim, Thiotepa, Topotecan Hydrochloride, Vincristine Sulfate
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Phase 1/2, Open-Label, Dose-Escalation And Expansion Study Of Entrectinib (Rxdx-101) In Pediatrics With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
A Phase 1/2, Open-Label, Dose-Escalation And Expansion Study Of Entrectinib (Rxdx-101) In Pediatrics With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
Enrollment Status: Active_not_recruiting
Publish Date: September 24, 2025
Intervention Type: Drug
Study Drug: Entrectinib
Study Phase: Phase 1/Phase 2
An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib)
An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib)
Enrollment Status: Active_not_recruiting
Publish Date: September 24, 2025
Intervention Type: Drug
Study Drugs: Dabrafenib, Trametinib
Study Phase: Phase 4
67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk Neuroblastoma: A Multi-center, Dose-escalation, Open-label, Non-randomized, Phase 1-2a Theranostic Clinical Trial
67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk Neuroblastoma: A Multi-center, Dose-escalation, Open-label, Non-randomized, Phase 1-2a Theranostic Clinical Trial
Enrollment Status: Terminated
Publish Date: September 16, 2025
Intervention Type: Drug
Study Drugs: 67Cu-SARTATE, 64Cu-SARTATE
Study Phase: Phase 1/Phase 2
A Phase I Study of Lenalidomide and Anti-GD2 Mab Ch14.18 +/- Isotretinoin in Patients With Refractory/Recurrent Neuroblastoma
A Phase I Study of Lenalidomide and Anti-GD2 Mab Ch14.18 +/- Isotretinoin in Patients With Refractory/Recurrent Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: September 05, 2025
Intervention Type: Other, Drug, Biological
Study Drugs: Dinutuximab, Isotretinoin, Lenalidomide
Study Phase: Phase 1
Open-label, Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
Open-label, Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
Enrollment Status: Completed
Publish Date: August 27, 2025
Intervention Type: Drug
Study Drug: Crizotinib
Study Phase: Phase 2
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 12, 2025
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide
Study Phase: Phase 3
A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients With Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) That Are Causing Significant Morbidity
A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients With Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) That Are Causing Significant Morbidity
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Drug
Study Drug: Mirdametinib
Study Phase: Phase 2
A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients With Relapsed/Refractory Neuroblastoma
A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients With Relapsed/Refractory Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: July 23, 2025
Intervention Type: Drug
Study Drugs: LY3295668 Erbumine, Topotecan, Cyclophosphamide
Study Phase: Phase 1
A Multicenter Open-label Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors, Pheochromocytoma and Paragangliomas (PPGL)
A Multicenter Open-label Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors, Pheochromocytoma and Paragangliomas (PPGL)
Enrollment Status: Active_not_recruiting
Publish Date: July 17, 2025
Intervention Type: Drug
Study Drug: Lutathera
Study Phase: Phase 2
A Phase 1/2 Trial of the MEK Inhibitor Selumetinib and Bromodomain Inhibitor With Durvalumab (MEDI4736), a PD-L1 Antibody for Sarcomas Including Malignant Peripheral Nerve Sheath Tumors (NF112)
A Phase 1/2 Trial of the MEK Inhibitor Selumetinib and Bromodomain Inhibitor With Durvalumab (MEDI4736), a PD-L1 Antibody for Sarcomas Including Malignant Peripheral Nerve Sheath Tumors (NF112)
Enrollment Status: Not_yet_recruiting
Publish Date: June 08, 2025
Intervention Type: Drug
Study Drug: Selumetinib
Study Phase: Phase 2
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab With or Without Eflornithine (DFMO) in Children With Relapsed, Refractory or Progressive Neuroblastoma
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab With or Without Eflornithine (DFMO) in Children With Relapsed, Refractory or Progressive Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: April 09, 2025
Intervention Type: Drug, Biological
Study Drugs: Dinutuximab, Eflornithine Hydrochloride, Irinotecan Hydrochloride, Sargramostim, Temozolomide
Study Phase: Phase 2
A Phase II Trial of Poly-ICLC for Progressive, Previously Treated Low-Grade Gliomas in Children and Young Adults With Neurofibromatosis Type 1
A Phase II Trial of Poly-ICLC for Progressive, Previously Treated Low-Grade Gliomas in Children and Young Adults With Neurofibromatosis Type 1
Enrollment Status: Terminated
Publish Date: March 21, 2025
Intervention Type: Drug
Study Drug: Poly ICLC
Study Phase: Phase 2
Next Generation Personalized Neuroblastoma Therapy (The NEPENTHE Trial)
Next Generation Personalized Neuroblastoma Therapy (The NEPENTHE Trial)
Enrollment Status: Terminated
Publish Date: February 19, 2025
Intervention Type: Other, Procedure, Behavioral, Drug, Genetic
Study Drugs: Ribociclib, Ceritinib
Study Phase: Phase 1
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: January 07, 2025
Intervention Type: Radiation, Drug, Procedure, Other
Study Phase: Phase 1
A Pilot Study of Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide in the Post-Consolidation Setting for High-Risk Neuroblastoma
A Pilot Study of Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide in the Post-Consolidation Setting for High-Risk Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: October 22, 2024
Intervention Type: Procedure, Drug, Radiation, Biological
Study Drugs: Dinutuximab, Irinotecan, Isotretinoin, Sargramostim, Temozolomide
Study Phase: Phase 2
An Open Label, Expanded Access Protocol Using 131I-METAIODOBENZYLGUANIDINE (131I-MIBG) Therapy +/- Vorinostat in Patients With Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma
An Open Label, Expanded Access Protocol Using 131I-METAIODOBENZYLGUANIDINE (131I-MIBG) Therapy +/- Vorinostat in Patients With Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma
Enrollment Status: No_longer_available
Publish Date: August 18, 2023
Intervention Type: Drug, Radiation
A Phase II Randomized Trial of Irinotecan/Temozolomide With Temsirolimus (NSC# 683864) or Chimeric 14.18 Antibody (Ch14.18) (NSC# 764038) in Children With Refractory, Relapsed or Progressive Neuroblastoma
A Phase II Randomized Trial of Irinotecan/Temozolomide With Temsirolimus (NSC# 683864) or Chimeric 14.18 Antibody (Ch14.18) (NSC# 764038) in Children With Refractory, Relapsed or Progressive Neuroblastoma
Enrollment Status: Completed
Publish Date: October 24, 2022
Intervention Type: Drug, Biological, Other
Study Drugs: Dinutuximab, Irinotecan Hydrochloride, Sargramostim, Temozolomide, Temsirolimus
Study Phase: Phase 2
A Phase I, Open-label, Dose Escalation Study of LDK378 in Pediatric Patients With Malignancies That Have a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)
A Phase I, Open-label, Dose Escalation Study of LDK378 in Pediatric Patients With Malignancies That Have a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)
Enrollment Status: Completed
Publish Date: June 09, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 19 Less Clinical Trials

58 Total Publications

Phase I Study of 131I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial.
Phase I Study of 131I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 23, 2025
Similar Doctors
Experienced in Hepatic Hemangioma
Dr. Gustavo J. Arriola
Neurosurgery | General Surgery
Experienced in Hepatic Hemangioma
Dr. Gustavo J. Arriola
Neurosurgery | General Surgery
640 S State St, 
Dover, DE 
 (58.5 miles away)
Languages Spoken:
English
See accepted insurances

Gustavo Arriola is a Neurosurgery specialist and a General Surgeon in Dover, Delaware. Dr. Arriola is rated as an Advanced provider by MediFind in the treatment of Hepatic Hemangioma. His top areas of expertise are Invertebral Disc Disease, Cervical Spondylosis, Spinal Stenosis, Herniated Disk, and Laminectomy.

Experienced in Hepatic Hemangioma
Dr. John T. Miura
General Surgery
Experienced in Hepatic Hemangioma
Dr. John T. Miura
General Surgery

Penn Endocrine And Oncologic Surgery Radnor

145 King Of Prussia Road, Floor 2, 
Radnor, PA 
 (12.1 miles away)
215-614-1963
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

John Miura is a General Surgeon in Radnor, Pennsylvania. Dr. Miura is rated as a Distinguished provider by MediFind in the treatment of Hepatic Hemangioma. His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Liposarcoma, Pancreaticoduodenectomy, and Hepato-Pancreato-Biliary Surgery. Dr. Miura is currently accepting new patients.

Experienced in Hepatic Hemangioma
Dr. Wellington J. Davis
Plastic Surgery | General Surgery
Experienced in Hepatic Hemangioma
Dr. Wellington J. Davis
Plastic Surgery | General Surgery

Lehigh Valley Physician Group

1210 S Cedar Crest Blvd, 110 Lvpg Pediatric Surgica, 
Allentown, PA 
 (46.7 miles away)
610-402-7999
Languages Spoken:
English
See accepted insurances

Wellington Davis is a Plastic Surgeon and a General Surgeon in Allentown, Pennsylvania. Dr. Davis is rated as an Advanced provider by MediFind in the treatment of Hepatic Hemangioma. His top areas of expertise are Hypoplasia of the Tibia with Polydactyly, Polydactyly, Velopharyngeal Insufficiency, Autosomal Cleft Palate, and Myringotomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Weiss's expertise for a condition
ConditionClose
    View All 14 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile